BlackRock emerges with $94m stake in CK Hutchison port trust

Hutchison Port Holdings Trust (HUPHY) reported 1H 2026 throughput of 11.7 million TEU, up 5% year-on-year. Total revenue and other income rose 10% to HKD6.2 billion, with operating profit up 30% to HKD2.8 billion and profit after tax attributable to unitholders up 85% to HKD491 million. Debt was HKD24.2 billion; net attributable debt HKD17.2 billion. CapEx rose 28% to HKD277 million.

Teck Resources Limited reported a strike at its Highland Valley Copper mine in British Columbia, reducing operations. The impact on production depends on the strike's duration. The company has contingency plans and aims for a fair collective agreement. Teck warned of potential effects on previously issued guidance due to the labor disruption.

Teck Resources Limited reports a strike at its Highland Valley Copper mine, leading to reduced operations. Production impact remains uncertain, depending on the strike's duration, according to the company.

Moderna and Merck's melanoma vaccine trial showed a 42% reduction in tumor recurrence and 38% in distant spread, impressing doctors. However, shares of both companies fell as investors questioned the vaccine's broader potential and commercial success. Analysts raised concerns about costs and competition. The full data will be presented at a medical conference.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced lung cancer death risk by 58% in a trial. Amgen reports median survival of 21.1 months vs. 12.7 months with Imfinzi alone. Imdelltra sales grew to $288M in Q2 2026, but represents only 2.9% of Amgen's total revenue. Analysts expect Amgen's revenue to grow 4% annually through 2030.

Johnson & Johnson reported positive results for its investigational drug JNJ-6143 in a Phase 1 prostate cancer trial, with 77% of patients showing a confirmed PSA decline. The company selected a 50-mg daily dose for Phase 2 testing. The drug is designed to target the androgen receptor and BRD4 protein. Johnson & Johnson acquired Halda Therapeutics, the drug's original developer, for $3.05 billion in 2025.